Table 4.

Hematologic and morphologic features of AML with IDH1^R132 and IDH2^R172 mutations

Patient No.	Mutation	Age/Sex	WHO	FAB	WBC (K/mL)	Hb (g/dL)	Platelets (K/ml)	Marrow Cellularity (%)	Blast (%)	Auer Rods	Dysplastic Features
1	IDH1	37/F	AML, NOS	M1	45.9	7.9	180	100	84	+++	Absent
2	IDH1	37/F	AML, NOS	M1	4.9	9.6	42	100	84	+	Mega
3	IDH1	51/F	AML, MLD	M1	4.9	9.6	31	80	53	NA	E, Mega
4	IDH1	73/F	AML, NOS	M1	16.9	10	92	95	67	++	E
5	IDH1	52/F	AML, NOS	M2	6.7	11.2	254	25	37	−	E (slight), Mega
6	IDH1	52/M	AML, NOS	M2	0.5	13.9	127	30	22	+	M, E (slight)
7	IDH1	53/M	AML, NOS	M2	0.3	12.5	45	90	27	−	M, E, Mega
8	IDH1	55/F	AML, NOS	M2	2.6	13.5	213	30	56	+	M
9	IDH1	52/F	AML, NOS	M5	1.4	13.6	119	80	24	−	M, E (Slight), Mega
10	IDH1	58/F	AML, NOS	M5	83.1	9.3	69	90	86	−	M, Mega
11	IDH1	77/F	AML, NOS	M5	8.6	12.8	225	90	80	NA	Mega
12	IDH1	62/M	AML, MLD	RAEB-T	0.7	10	291	40	44	−	Absent
13	IDH2	48/F	AML, NOS	M1	1.7	8.2	99	80	61	+	M, E
14	IDH2	59/M	AML, NOS	M1	1.8	9.7	238	60	61	+	E
15	IDH2	76/F	AML, NOS	M1	11.8	9.4	18	70	73	−	Absent
16	IDH2	22/F	AML, NOS	M2	1.7	8.4	79	70	42	+++	M, E

AML, NOS, AML not otherwise specified; AML, MLD; AML with myelodysplasia-related changes; RAEB-T, refractory anemia with excess blast in transformation; NA, not available; M, myeloid; E, erythroid; Mega, megakaryocytes